MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - pharmaceuticals
- ASTRAZENECA PHARMA - DIVIS LABORATORIES
ASTRAZENECA PHARMA vs DIVIS LABORATORIES - Comparison Results
ASTRAZENECA PHARMA Change
AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
DIVIS LABORATORIES 
Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More
Current Valuations
| ASTRAZENECA PHARMA | DIVIS LABORATORIES | ASTRAZENECA PHARMA/ DIVIS LABORATORIES |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 93.6 | 45.2 | 207.2% | View Chart |
| P/BV | x | 28.4 | 8.3 | 342.5% | View Chart |
| Dividend Yield | % | 0.0 | 0.7 | - |
Financials
 ASTRAZENECA PHARMA  DIVIS LABORATORIES |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| ASTRAZENECA PHARMA Mar-18 |
DIVIS LABORATORIES Mar-19 |
ASTRAZENECA PHARMA/ DIVIS LABORATORIES |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,278 | 1,639 | 78.0% | |
| Low | Rs | 883 | 1,115 | 79.2% | |
| Sales per share (Unadj.) | Rs | 228.4 | 186.3 | 122.6% | |
| Earnings per share (Unadj.) | Rs | 10.4 | 51.0 | 20.3% | |
| Cash flow per share (Unadj.) | Rs | 16.3 | 57.3 | 28.4% | |
| Dividends per share (Unadj.) | Rs | 0 | 16.00 | 0.0% | |
| Dividend yield (eoy) | % | 0 | 1.2 | 0.0% | |
| Book value per share (Unadj.) | Rs | 98.8 | 261.8 | 37.7% | |
| Shares outstanding (eoy) | m | 25.00 | 265.47 | 9.4% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 4.7 | 7.4 | 64.0% | |
| Avg P/E ratio | x | 104.2 | 27.0 | 385.7% | |
| P/CF ratio (eoy) | x | 66.4 | 24.0 | 276.5% | |
| Price / Book Value ratio | x | 10.9 | 5.3 | 207.9% | |
| Dividend payout | % | 0 | 31.4 | 0.0% | |
| Avg Mkt Cap | Rs m | 27,008 | 365,592 | 7.4% | |
| No. of employees | `000 | 1.4 | 11.8 | 11.4% | |
| Total wages/salary | Rs m | 1,535 | 5,423 | 28.3% | |
| Avg. sales/employee | Rs Th | 4,210.9 | 4,175.1 | 100.9% | |
| Avg. wages/employee | Rs Th | 1,132.2 | 457.7 | 247.4% | |
| Avg. net profit/employee | Rs Th | 191.1 | 1,141.8 | 16.7% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 5,710 | 49,463 | 11.5% | |
| Other income | Rs m | 123 | 1,556 | 7.9% | |
| Total revenues | Rs m | 5,833 | 51,019 | 11.4% | |
| Gross profit | Rs m | 463 | 18,718 | 2.5% | |
| Depreciation | Rs m | 147 | 1,689 | 8.7% | |
| Interest | Rs m | 0 | 35 | 0.0% | |
| Profit before tax | Rs m | 438 | 18,551 | 2.4% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 179 | 5,023 | 3.6% | |
| Profit after tax | Rs m | 259 | 13,527 | 1.9% | |
| Gross profit margin | % | 8.1 | 37.8 | 21.4% | |
| Effective tax rate | % | 40.8 | 27.1 | 150.8% | |
| Net profit margin | % | 4.5 | 27.3 | 16.6% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 3,209 | 46,501 | 6.9% | |
| Current liabilities | Rs m | 2,070 | 8,468 | 24.4% | |
| Net working cap to sales | % | 20.0 | 76.9 | 26.0% | |
| Current ratio | x | 1.6 | 5.5 | 28.2% | |
| Inventory Days | Days | 72 | 131 | 55.3% | |
| Debtors Days | Days | 35 | 86 | 40.7% | |
| Net fixed assets | Rs m | 790 | 25,797 | 3.1% | |
| Share capital | Rs m | 50 | 531 | 9.4% | |
| "Free" reserves | Rs m | 2,419 | 68,962 | 3.5% | |
| Net worth | Rs m | 2,469 | 69,493 | 3.6% | |
| Long term debt | Rs m | 0 | 0 | - | |
| Total assets | Rs m | 4,605 | 80,383 | 5.7% | |
| Interest coverage | x | NM | 531.0 | - | |
| Debt to equity ratio | x | 0 | 0 | - | |
| Sales to assets ratio | x | 1.2 | 0.6 | 201.5% | |
| Return on assets | % | 5.6 | 16.9 | 33.3% | |
| Return on equity | % | 10.5 | 19.5 | 53.9% | |
| Return on capital | % | 17.7 | 26.7 | 66.3% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 0 | 24.6 | 0.0% | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | NA | 12,187 | 0.0% | |
| Fx inflow | Rs m | 300 | 41,238 | 0.7% | |
| Fx outflow | Rs m | 2,015 | 12,405 | 16.2% | |
| Net fx | Rs m | -1,715 | 28,833 | -5.9% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 88 | 9,543 | 0.9% | |
| From Investments | Rs m | -94 | -6,854 | 1.4% | |
| From Financial Activity | Rs m | NA | -2,459 | 0.0% | |
| Net Cashflow | Rs m | -6 | 230 | -2.5% | |
Share Holding
| Indian Promoters | % | 0.0 | 52.0 | - | |
| Foreign collaborators | % | 75.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 0.3 | 11.8 | 2.5% | |
| FIIs | % | 15.7 | 19.0 | 82.6% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 9.1 | 17.2 | 52.9% | |
| Shareholders | 12,856 | 31,796 | 40.4% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASTRAZENECA PHARMA With: CADILA HEALTHCARE TTK HEALTHCARE SHASUN PHARMA DISHMAN PHARMA J.B.CHEMICALS
Compare ASTRAZENECA PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Today's Market
Slow Economy? There's Still Good Money to Be Made in the Markets(Podcast)
Indian stock markets mostly remained in the negative zone during the week except for Wednesday.
Related Views on News
DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)
Feb 6, 2020 | Updated on Feb 6, 2020For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
DIVIS LABORATORIES Announces Quarterly Results (2QFY20); Net Profit Down 10.3% (Quarterly Result Update)
Nov 11, 2019 | Updated on Nov 11, 2019For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)
Oct 10, 2019 | Updated on Oct 10, 2019Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.
DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)
Aug 13, 2019 | Updated on Aug 13, 2019For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)
Aug 8, 2019 | Updated on Aug 8, 2019For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
More Views on NewsMost Popular
The Next Few Days Are Crucial for Smallcap Investors - And 3 Must-Buy Stocks(Profit Hunter)
Feb 19, 2020While I have been writing about the rebound in smallcaps for quite some time now... I have shied from the question - When exactly is the smallcap rebound happening. Well, the answer is now.
This Smallcap Stock Could be the Next Titan (Up 1,400% in 10 Years)(Profit Hunter)
Feb 11, 2020A blueprint to latch on to the next 'Crorepati' stock - and an event I hope you won't miss on any account.
Here's Why I Recommended 15 Stocks in One Day Flat(Views On News)
Feb 14, 2020This proven strategy can give big returns in quick time.
The Top 8 Trading Mistakes You Should Avoid(Fast Profits Daily)
Feb 18, 2020Avoid these mistakes and your trading will turn much more profitable.
These Rebirth of India Stocks Are Raring to Compete with Tesla(The 5 Minute Wrapup)
Feb 17, 2020There are Indian stocks which can soar like Tesla in the long-run.
MoreOUR TOP 5 IDEAS
- Free Guide on How to Profit from Sensex 100,000.
- 7 Stocks to Ride the Coming Rebirth of India Rally. Full Details Here...
- A Guide to some of the Most Lucrative Stocks in the Market. Download For Free!
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Revealed: Top 7 Stocks to Consider Buying Right Now...
ASTRAZENECA PHARMA SHARE PRICE
Feb 20, 2020 (Close)
TRACK ASTRAZENECA PHARMA
- Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ASTRAZENECA PHARMA
ASTRAZENECA PHARMA 5-YR ANALYSIS
COMPARE ASTRAZENECA PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.